

DAFTAR PUSTAKA

- Gibson E, Mahdy H. Anatomy, Abdomen and Pelvis, Ovary. In: StatPearls .Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK545187> [Updated 2021 Jul 26].
- Saksouk F. and Jhonson S., Recognition of the Ovaries and Ovarian Origin of Pelvic Masses with CT: RadioGraphics RSNA: 2004; 24:S133–S146, Published online 10.1148/rg.24si045507
- Blaustein, A. (1977). Anatomy and Histology of Human Ovary. In: Blaustein, A. (eds) Pathology of Female Genital Tract. Springer, New York, NY. https://doi.org/10.1007/978-1-4757-6143-6_19
- Clemente, Carmine D. (2011). Anatomy: A Regional Atlas of Human Body. Sixth Ed. Wolters Kluwer, Lippincott Williams & Wilkins; Plate 335
- Gray, Henry, Susan Standring, Harold Ellis, and B.K.B. Berkovitz. Gray's Anatomy: The anatomical basis of clinical practice., 39th ed. Edinburgh: Elsevier Churchill Livingstone, 2005
- Williams CJ, Erickson GF. Morphology and Physiology of the Ovary. [Updated 2012 Jan 30]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDTText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK278951/>
- Orsi, N.M., Baskind, N.E., Cummings, M. (2014). Anatomy, Development, Histology, and Normal Function of the Ovary. In: Wilkinson, N. (eds) Pathology of the Ovary, Fallopian Tube and Peritoneum. Essentials of Diagnostic Gynecological Pathology. Springer, London. https://doi.org/10.1007/978-1-4471-2942-4_1
- Khan et al, Frequency of Ovarian Tumors According to WHO Histological Classification and Their Association to Age at Diagnosis (2017). Annals of King Edward Medical University Lahore Pakistan: DOI:10.21649/akemu.v23i2.1579
- Chen V.W, et al. Pathology and classification of ovarian tumors. Cancer. 2003 May 15;97(10 Suppl):2631-42. doi: 10.1002/cncr.11345. PMID: 12733128.
- Taylor et al., Multimodality Imaging Approach to Ovarian Neoplasm with Pathologic Correlation. RadioGraphics 2021; 41:289–315: <https://doi.org/10.1148/rg.2021200086>
- Jung S. et al, CT and MR Imaging of Ovarian Tumors with Emphasis on Differential Diagnosis: RSNA RadioGraphics 2002; 22:1305–1325 Published online 10.1148/rg.226025033

- Reid et al. Epidemiology of Ovarian Cancer, Review: Cancer Biol Med 2017. doi: 10.20892/j.issn.2095-3941.2016.0084
- Momenimovahed et al., Ovarian Cancer in the World: Epidemiology and Risk Factors: International Journal of Woman's Health 2019: 11 287 - 299
- Jeong et al., Imaging Evaluation of Ovarian Masses, RSNA:RadioGraphics 2000; 20:1445–1470 <https://doi.org/10.1148/radiographics.20.5.g00se101445>
- Noela Francisca, Nuryanto Kartiwa., Epidemiology Data of Ovarian Cancer in Dr.Cipto Mangunkusumo Hospital, Jakarta. Indonesian Journal of Obstetric and Gynecologic: April 2016; Vol 4, No 2: 101-106
- Ramayuda IBG, Mardiyana L, Erawati D, Yuliati I., Diagnostic value of abdominal CT scan in ovarian tumors in Dr. Soetomo General Academic Hospital: Maj Obs Gin 2021; 29: 45-52: DOI: <http://dx.doi.org/10.20473/mog.V29I22021.45-52>
- Melin A, Sparen P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21(5):1237–1242. doi:10.1093/humrep/dei462
- Stewart LM, Holman CAJ, Aboagye-Sarfo P, Finn JC, Preen DB, Hart R. In vitro fertilization, endometriosis, nulliparity and ovarian cancer risk. Gynecol Oncol. 2013;128(2):260–264. doi:10.1016/j.ygyno.2012.10.023
- Jordan SJ, Green AC, Whiteman DC, Webb PM. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol. 2007;107(2):223–230. doi:10.1016/j.ygyno.2007.06.006
- Budiana ING, Angelina M, Tjokorda GAP., Ovarian Cancer: Pathogenesis and Current Recommendations for Prophylactic Surgery., Journal of Turkish-German Gynecological Association 2019; 20: 47-54
- Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008 Apr;27(2):151-60. doi: 10.1097/PGP.0b013e318161e4f5. PMID: 18317228; PMCID: PMC2794425.
- Lurie et al., Symptom Presentation in Invasive Ovarian Carcinoma by Tumor Histological Type and Grade in a Multi-ethnic Population: A Case Analysis. Journal of Gynecol Oncol. 2010 November; 119 (2): 278– 284. Doi:10.1016 /j.ygyno. 2010. 05. 028.
- Jelovac D., Armstrong D., Recent Progress in the Diagnosis and Treatment of Ovarian Cancer: CA: Cancer Journal for Clinicians 2011; 61:183–203; American Cancer Society, Inc. doi:10.3322/caac.20113.

- Muhabat et al. Clinical Presentations of Ovarian Tumor: Open Journal of Obstetrics and Gynecology, 2016, 6, 205-209, <http://www.scirp.org/journal/ojog> <http://dx.doi.org/10.4236/ojog.2016.64026>
- Goff B et al., Frequency of Symptoms of Ovarian Cancer in Woman Presenting in Primary Care Clinics. JAMA: Journal of American Medical Association, June 9, 2004 – Vol 291, No.22
- Arora T et al. Ovarian Cancer. [Updated 2023 Jun 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing 2023 January. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK567760/>
- Doubeni et al., Diagnosis and Management of Ovarian Cancer., Journal of America Family Physician: Volume 93, Number 11, June 2016. Available at: <http://www.aafp.org/afp/2016/0601/p937-s1.html>.
- Rupa R. et al. Imaging Recommendations for Diagnosis, Staging, and Management of Ovarian and Fallopian Tube Cancers: Indian Journal of Medical and Paediatric Oncology Vol. 44 No. 1/2023 DOI <https://doi.org/10.1055/s-0042-1759518>.
- Fernandes M. et al. CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know – Radiology in Training, RSNA: Radiology 2022; 304:516–526 <https://doi.org/10.1148/radiol.212737>
- Khattak Y. et al., Ovarian Masses: Is Multi-detector Computed Tomography a Reliable Imaging Modality? In Research Article: Asian Pacific Journal of Cancer Prevention, Vol 14, 2013 pp: 2627 – 2630.
- Suppiah S, Kamal SH, MZ, Hassan, Characterization of Adnexal Masses Using Multidetector Contrast- Enhanced CT Scan – Recognising Common Pitfalls that Masquerade as Ovarian Cancer., Pertanika J. Sci. & Technol. 2017, 25 (1): 337 - 352
- Redondo A et al., SEOM Clinical Guideline in Ovarian Cancer., Journal of Clinical and Translational Oncology. December 2020. Doi: <https://doi.org/10.1007/s12094-020-02545-x>
- Guerriero S et al., Transvaginal Ultrasound and Computed Tomography combined with Clinical Parameters and CA-125 determinations in the differential diagnosis of persistent ovarian cysts in premenopausal women. Ultrasound Obstet. Gynecol. 1997, 9, 339–343.
- Lupean et al., Computer Tomography in the Diagnosis of Ovarian Cysts: The Role of Fluid Attenuation Values., Healthcare 2020, 8, 398; doi:10.3390/healthcare8040398

- Song-Mee Cho et al. CT Differentiation of Mucinous dan Serous Cystadenocarcinoma: Journal of Korean Society of Radiology: 1999;41 PP:989-994
- Boos J. et al. Ovarian Cancer: Prevalence in Incidental Simple Adnexal Cysts Initially Identified in CT Examinations of the Abdomen and Pelvis, RSNA Radiology: Volume 286: Number 1—January 2018
- Choi et al. CT Findings of Clear Cell Carcinoma of the Ovary: Comput Assist Tomogr & Volume 30, Number 6, November/December 2006
- Lertkhachonsuk et al. Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors: J. Obstet. Gynaecol. Res. Vol. 46, No. 11: 2287–2291, November 2020. doi:10.1111/jog.14427
- Junhon Guo et al. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta- analysis. De Gruyter Open Med. 2017; 12: 131-137. DOI 10.1515/med-2017-0020
- Sagi-Dain et al. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature: Int J Biol Markers 2015; 30(4): e394-e400. DOI: 10.5301/ijbm.5000158
- Ji Hui Choi et al. Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. Obstet Gynecol Sci 2018;61(3):344-351. <https://doi.org/10.5468/ogs.2018.61.3.344>
- Kristjansdottir et al. Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ: Clin Proteom 10, 4 (2013). <https://doi.org/10.1186/1559-0275-10-4>
- Lusela Pillay & Reubina Wadee (2021) A retrospective study of the epidemiology and histological subtypes of ovarian epithelial neoplasms at Charlotte Maxeke Johannesburg Academic Hospital, Southern African Journal of Gynaecological Oncology, 13:1, 26-35, DOI: 10.1080/20742835.2021.1962084
- Ramba L. et al., CT Hounsfield Numbers of Soft Tissues on Unenhanced Abdominal CT Scans: Variability Between Two Different Manufacturers' MDCT Scanners: AJR 2014; 203:1013–1020. DOI:10.2214/AJR.12.10037
- Sudhyadhom A (2020) On the molecular relationship between Hounsfield Unit (HU), mass density, and electron density in computed tomography (CT). PLoS ONE 15 (12): e0244861 <https://doi.org/10.1371/journal.pone.0244861>

Boos E A. et al., Clinical Value Analytes in Cyst Fluid from Ovarian Tumors:
Thesis University of Nijmegen-With Summary in Dutch. ISBN: 90-
9016947-4 (2003)

Vitiazeva et al., The O-Linked Glycome and Blood Group Antigens ABO on
Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian
Tumors: PLoS ONE 10(6): e0130197. doi:10.1371/journal.pone.0130197

LAMPIRAN 1



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari..MMed,PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 179/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 18 Maret 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24030138	No Sponsor	
Peneliti Utama	dr. Arizal	Sponsor	
Judul Peneliti	Korelasi Nilai Atenuasi Cairan Berdasarkan CT Scan Abdomen Dengan Tumor Marker Ca 125 dan CEA Pada Tumor Ovarium Tipe Musinous dan Serous		
No Versi Protokol	1	Tanggal Versi	1 Maret 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 18 Maret 2024 sampai 18 Maret 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 2

Hasil Analisis Deskriptif

Type Tumor					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	MUCINOUS CYSTADENOMA	14	16.1	16.1	16.1
	MUSINOUS CYSTADENOCARCINO	17	19.5	19.5	35.6
	SEROUS CYSTADENOCARCINOMA	42	48.3	48.3	83.9
	SEROUS CYSTADENOMA	14	16.1	16.1	100.0
	Total	87	100.0	100.0	

Descriptive Statistics					
	N	Minimum	Maximum	Mean	Std. Deviation
Usia	87	15.00	79.00	46.1264	14.46230
HU CT PRE KONTRAS	87	2.00	52.00	20.5061	8.11646
HU CT POST KONTRAS	75	5.00	62.00	22.3333	9.73213
CA 125	84	1.38	2840.00	298.3467	383.03204
CEA	56	.50	1125.00	32.6818	154.13864
Valid N (listwise)	48				

Descriptives									
		N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
						Lower Bound	Upper Bound		
Usia	SEROUS CYSTADENOCARCINOMA	42	51.7381	10.46728	1.61514	48.4763	54.9999	20.00	79.00
	SEROUS CYSTADENOMA	14	44.8571	15.63456	4.17851	35.8300	53.8843	15.00	65.00
	MUSINOUS CYSTADENOCARCINO	17	36.5882	15.19070	3.68429	28.7779	44.3986	15.00	61.00
	MUCINOUS CYSTADENOMA	14	42.1429	16.43569	4.39262	32.6532	51.6325	15.00	62.00
	Total	87	46.1264	14.46230	1.55052	43.0441	49.2088	15.00	79.00
HU CT PRE KONTRAS	SEROUS CYSTADENOCARCINOMA	42	23.7857	6.22558	.96063	21.8457	25.7257	12.00	38.00
	SEROUS CYSTADENOMA	14	16.1450	6.39495	1.70912	12.4527	19.8373	7.00	29.00
	MUSINOUS CYSTADENOCARCINO	17	19.1765	10.98428	2.66408	13.5289	24.8241	8.00	52.00
	MUCINOUS CYSTADENOMA	14	16.6429	7.11020	1.90028	12.5375	20.7482	2.00	27.00
	Total	87	20.5061	8.11646	.87018	18.7762	22.2359	2.00	52.00
HU CT POST KONTRAS	SEROUS CYSTADENOCARCINOMA	34	26.5588	9.07274	1.55596	23.3932	29.7245	12.00	62.00
	SEROUS CYSTADENOMA	14	16.8571	6.15134	1.64401	13.3055	20.4088	9.00	31.00
	MUSINOUS CYSTADENOCARCINO	17	21.7059	11.16224	2.70724	15.9668	27.4450	9.00	53.00
	MUCINOUS CYSTADENOMA	10	16.7000	7.11883	2.25117	11.6075	21.7925	5.00	28.00
	Total	75	22.3333	9.73213	1.12377	20.0942	24.5725	5.00	62.00
CA 125	SEROUS CYSTADENOCARCINOMA	40	506.9873	444.25374	70.24268	364.9080	649.0665	22.20	2840.00
	SEROUS CYSTADENOMA	14	131.1929	145.83144	38.97509	46.9923	215.3934	1.38	476.60
	MUSINOUS CYSTADENOCARCINO	16	144.7075	225.15621	56.28905	24.7302	264.6848	4.98	928.90
	MUCINOUS CYSTADENOMA	14	44.9721	51.41814	13.74208	15.2842	74.6601	8.02	188.00
	Total	84	298.3467	383.03204	41.79222	215.2236	381.4697	1.38	2840.00
CEA	SEROUS CYSTADENOCARCINOMA	26	47.1792	220.22147	43.18898	-41.7701	136.1286	.50	1125.00
	SEROUS CYSTADENOMA	9	1.6711	.86798	.28933	1.0039	2.3383	.63	3.63
	MUSINOUS CYSTADENOCARCINO	14	40.6029	74.90773	20.01993	-2.6476	83.8533	.50	200.00
	MUCINOUS CYSTADENOMA	7	2.8629	4.45034	1.68207	-1.2530	6.9787	.50	12.75
	Total	56	32.6818	154.13864	20.59764	-8.5968	73.9604	.50	1125.00

Hasil Uji Normalitas

Tests of Normality						
	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
HU CT PRE KONTRAS	.138	48	.023	.950	48	.041
HU CT POST KONTRAS	.131	48	.038	.892	48	.000
CA 125	.249	48	.000	.565	48	.000
CEA	.462	48	.000	.212	48	.000

a. Lilliefors Significance Correction

Hasil Uji Wilcoxon

Ranks				
		N	Mean Rank	Sum of Ranks
HU CT POST KONTRAS - HU CT PRE KONTRAS	Negative Ranks	9 ^a	23.22	209.00
	Positive Ranks	53 ^b	32.91	1744.00
	Ties	13 ^c		
	Total	75		

a. HU CT POST KONTRAS < HU CT PRE KONTRAS
b. HU CT POST KONTRAS > HU CT PRE KONTRAS
c. HU CT POST KONTRAS = HU CT PRE KONTRAS

Test Statistics ^a	
	HU CT POST KONTRAS - HU CT PRE KONTRAS
Z	-5.422 ^b
Asymp. Sig. (2-tailed)	.000
a. Wilcoxon Signed Ranks Test	
b. Based on negative ranks.	

Hasil Uji Korelasi

Correlations						
			HU CT PRE KONTRAS	HU CT POST KONTRAS	CA 125	CEA
Spearman's rho	HU CT PRE KONTRAS	Correlation Coefficient	1.000	.932**	.402**	-.039
		Sig. (2-tailed)	.	.000	.000	.774
		N	87	75	84	56
	HU CT POST KONTRAS	Correlation Coefficient	.932**	1.000	.452**	.049
		Sig. (2-tailed)	.000	.	.000	.730
		N	75	75	72	51
	CA 125	Correlation Coefficient	.402**	.452**	1.000	-.074
		Sig. (2-tailed)	.000	.000	.	.597
		N	84	72	84	53
	CEA	Correlation Coefficient	-.039	.049	-.074	1.000
		Sig. (2-tailed)	.774	.730	.597	.
		N	56	51	53	56

** . Correlation is significant at the 0.01 level (2-tailed).

ROC

SEROUS CYSTADENOCARCINOMA dan SEROUS CYSTADENOMA

. cutpt Type huctprekontras, noadjust

Empirical cutpoint estimation

Method : Liu
 Reference variable : Type (0=neg, 1=pos)
 Classification variable : huctprekontras
 Empirical optimal cutpoint : 26
 Sensitivity at cutpoint : 0.29
 Specificity at cutpoint : 0.93
 Area under ROC curve at cutpoint : 0.61

cutpt Type huctpostkontras, noadjust

Empirical cutpoint estimation

Method : Liu
 Reference variable : Type (0=neg, 1=pos)

Classification variable : huctpostkontras
Empirical optimal cutpoint : 26
Sensitivity at cutpoint : 0.38
Specificity at cutpoint : 0.88
Area under ROC curve at cutpoint : 0.63

cutpt Type ca125, noadjust

Empirical cutpoint estimation
Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : ca125
Empirical optimal cutpoint : 101.5
Sensitivity at cutpoint : 0.72
Specificity at cutpoint : 0.29
Area under ROC curve at cutpoint : 0.51

cutpt Type cea, noadjust

Empirical cutpoint estimation
Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : cea
Empirical optimal cutpoint : 1.05
Sensitivity at cutpoint : 0.50
Specificity at cutpoint : 1.00
Area under ROC curve at cutpoint : 0.75

MUSINOUS CYSTADENOCARCINOMA dan MUCINOUS CYSTADENOMA

cutpt Type huctprekontras, noadjust

Empirical cutpoint estimation
Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : huctprekontras
Empirical optimal cutpoint : 19
Sensitivity at cutpoint : 0.29
Specificity at cutpoint : 0.71
Area under ROC curve at cutpoint : 0.50

cutpt Type huctpostkontras, noadjust

Empirical cutpoint estimation

Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : huctpostkontras
Empirical optimal cutpoint : 18
Sensitivity at cutpoint : 0.53
Specificity at cutpoint : 0.70
Area under ROC curve at cutpoint : 0.61

cutpt Type ca125, noadjust

Empirical cutpoint estimation

Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : ca125
Empirical optimal cutpoint : 23.74
Sensitivity at cutpoint : 0.81
Specificity at cutpoint : 0.57
Area under ROC curve at cutpoint : 0.69

cutpt Type cea, noadjust

Empirical cutpoint estimation

Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : cea
Empirical optimal cutpoint : 94
Sensitivity at cutpoint : 0.86
Specificity at cutpoint : 0.57
Area under ROC curve at cutpoint : 0.71

SEROUS CYSTADENOCARCINOMA dan MUSINOUS CYSTADENOCARCINOMA

cutpt Type huctprekontras, noadjust

Empirical cutpoint estimation

Method : Liu
Reference variable : Type (0=neg, 1=pos)
Classification variable : huctprekontras
Empirical optimal cutpoint : 17
Sensitivity at cutpoint : 0.88
Specificity at cutpoint : 0.65
Area under ROC curve at cutpoint : 0.76

. cutpt Type huctpostkontras, noadjust

Empirical cutpoint estimation
 Method : Liu
 Reference variable : Type (0=neg, 1=pos)
 Classification variable : huctpostkontras
 Empirical optimal cutpoint : 22
 Sensitivity at cutpoint : 0.68
 Specificity at cutpoint : 0.71
 Area under ROC curve at cutpoint : 0.69

. cutpt Type ca125, noadjust

Empirical cutpoint estimation
 Method : Liu
 Reference variable : Type (0=neg, 1=pos)
 Classification variable : ca125
 Empirical optimal cutpoint : 276.01999
 Sensitivity at cutpoint : 0.75
 Specificity at cutpoint : 0.94
 Area under ROC curve at cutpoint : 0.84

cutpt Type cea, noadjust

Empirical cutpoint estimation
 Method : Liu
 Reference variable : Type (0=neg, 1=pos)
 Classification variable : cea
 Empirical optimal cutpoint : 1.67
 Sensitivity at cutpoint : 0.23
 Specificity at cutpoint : 0.50
 Area under ROC curve at cutpoint : 0.37

SEROUS CYSTADENOMA dan MUCINOUS CYSTADENOMA

cutpt Type huctprekontras, noadjust

Empirical cutpoint estimation
 Method : Liu
 Reference variable : Type (0=neg, 1=pos)
 Classification variable : huctprekontras
 Empirical optimal cutpoint : 16
 Sensitivity at cutpoint : 0.64
 Specificity at cutpoint : 0.64
 Area under ROC curve at cutpoint : 0.64

cutpt Type huctpostkontras, noadjust

Empirical cutpoint estimation

Method	: Liu
Reference variable	: Type (0=neg, 1=pos)
Classification variable	: huctpostkontras
Empirical optimal cutpoint	: 15
Sensitivity at cutpoint	: 0.70
Specificity at cutpoint	: 0.57
Area under ROC curve at cutpoint	: 0.64

.

. cutpt Type ca125, noadjust

Empirical cutpoint estimation

Method	: Liu
Reference variable	: Type (0=neg, 1=pos)
Classification variable	: ca125
Empirical optimal cutpoint	: 14.64
Sensitivity at cutpoint	: 0.71
Specificity at cutpoint	: 0.29
Area under ROC curve at cutpoint	: 0.50

cutpt Type cea, noadjust

Empirical cutpoint estimation

Method	: Liu
Reference variable	: Type (0=neg, 1=pos)
Classification variable	: cea
Empirical optimal cutpoint	: 2.21
Sensitivity at cutpoint	: 0.29
Specificity at cutpoint	: 0.89
Area under ROC curve at cutpoint	: 0.59

LAMPIRAN 3

CURRICULUM VITAE

A. Data Pribadi

- Nama : dr. Arizal
- Tempat & Tanggal Lahir : Bontang, 18 April 1984
- Agama : Islam
- Alamat : Jl.Agis Pulak, Kab. Tana Tidung
- Nama Ayah / Ibu : Salman Siata / Hj. Nurlela
- Isteri : Ratih Eka Pratiwi
- Anak : Khalifah A. Safaraz & Fiba A. Maulidina

B. Riwayat Pendidikan

- TK : TK YPK Bontang
- SD : SD YPK Bontang
- SMP : SMP YPK Bontang
- SMA : SMA YPK Bontang
- Perguruan Tinggi : Fakultas Kedokteran UNHAS, Makassar
- PPDS : Ilmu Radiologi, FK UNHAS, Makassar

C. Riwayat Pekerjaan

- PTT Pusat Departemen Kesehatan di PKM Long Alango, Kab. Malinau, Kalimantan Utara (2008 – 2010)
- Dokter Umum PKM Sesayap Hilir, Kab. Tana Tidung, Kalimantan Utara (2010 – 2020)

D. Makalah pada Seminar / Konferensi Ilmiah Nasional

“13 Months Old Female Infant With Type IV of Caudal Regression Syndrome” dibawakan pada Malaysian Congress of Radiology, Connexion Conference Centre (CCEC), Kuala Lumpur, Malaysia (21 – 23 Juli 2023).